Contemporary OB/GYN/LinkedIn
Jan 18, 2026, 07:48
DSMB Review Confirms Safety of Brexanolone for PPD – Contemporary OB/GYN
Contemporary OB/GYN shared a post on LinkedIn:
“A phase 3 trial of Lipocine Inc.‘s oral formulation of brexanolone, LPCN 1154, for postpartum depression, will continue without any modification following the completion of a second independent Data Safety Monitoring Board review.
In the second and last review, the DSMB found no safety concerns in the trial.
More details and more on the makeup of the trial.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 1, 2026, 03:13International Expert Recommendations in Emerging Reproductive Science – ESHRE
-
Apr 30, 2026, 18:45AI in Ultrasound Follicular Monitoring Moves Toward Clinical Decision Support – RBMO
-
Apr 30, 2026, 11:42ASRM Encourages Registration for Conference on Practice Growth and Innovation
-
Apr 30, 2026, 11:26ESHRE and ALPHA Launch Global Survey to Update ART Laboratory KPIs
-
Apr 30, 2026, 11:10Susanne Johnson: Advanced Gynaecology Ultrasound Course Day 2
-
Apr 30, 2026, 11:02Platelets Reduce Oxidative Stress Damage in Human Endometrial Stromal Cells in Vitro – RBMO
-
Apr 30, 2026, 10:57GREEG Day 2026: Elevate Your Ultrasound Expertise – GREEG
-
Apr 30, 2026, 10:49Up to Two-Thirds of Elite Female Athletes Experience Irregular Periods – Fertility Plus
-
Apr 30, 2026, 10:47Applications for the ESHRE5 Young Ambassadors 2026 are Still OPEN, But Not for Long! – ESHRE